Dr. Renee M Sarett, MD Emergency Medicine - Hospice and Palliative Medicine Medicare: Accepting Medicare Assignments Practice Location: 144 Us Route 1 Ste 2, Scarborough, ME 04074 Phone: 207-396-7606 |
Philip Capriotti, Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 55 Spring St, Scarborough, ME 04074 Phone: 207-883-3988 |
Erik N Steele, DO Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 153 Us Route 1, Scarborough, ME 04074 Phone: 207-799-8596 Fax: 207-799-1730 |
Dr. Mark Alan Rautenberg, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 17 Merrill Brook Dr, Scarborough, ME 04074 Phone: 207-883-4145 Fax: 207-490-7452 |
Dr. Jeanne E Scheddel, D.O. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 55 Spring St, Scarborough, ME 04074 Phone: 207-885-3988 |
Mark M Durcan, MD Emergency Medicine Medicare: May Accept Medicare Assignments Practice Location: 273 Payne Rd, Scarborough, ME 04074 Phone: 207-618-9355 Fax: 207-618-9356 |
News Archive
CSG Partners, LLC, served as the exclusive financial advisor to Home Medical Equipment, on its recent transition to becoming 100% owned by its Employee Stock Ownership Plan (ESOP).
There are many health effects that a patient may need to overcome after winning a battle against cancer. Cancer treatments can affect the patient's balance, agility, coordination, prompt weight gain and other physical ailments. At Nationwide Children's Hospital, beating cancer doesn't mark the end of a child's treatment regimen. A new exercise program at the hospital helps pediatric cancer survivors and those in remission regain both physical strength and confidence.
The Catalysis Foundation for Health (Catalysis), a 501 (c) (3) non-profit entity dedicated to developing sustainable diagnostics for the developing world, announced today that it has received a $5 million grant from the Bill & Melinda Gates Foundation. The grant money will be used to discover new tuberculosis (TB) biomarkers that can be used to improve diagnostic tests and potentially develop more effective TB treatments.
Pfizer Inc. announced today that 14 abstracts for tofacitinib, an investigational oral Janus kinase (JAK) inhibitor for the treatment of adults with moderate-to-severe active rheumatoid arthritis (RA), will be presented at the American College of Rheumatology (ACR) / Association of Rheumatology Health Professionals (ARHP) 2012 Annual Meeting, which is being held November 9-14 in Washington, D.C.
› Verified 9 days ago